Findings

What do systematic reviews say?

8 questions · 8 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 1 · 12.5%Very low 0 · 0%Low 4 · 50%Moderate 3 · 37.5%High 0 · 0%

Non‐platinum therapies vs platinum combination

Grade 3 or higher hematological toxicity for platinum therapies ‐ anemia · non‐small cell lung cancer in the elderly population

Non‐platinum therapies may leads to higher grade 3 or higher hematological toxicity for platinum therapies ‐… compared with platinum combination (low certainty).

1 finding from 1 review

Chemotherapy for advanced non‐small cell lung cancer in the elderly population 2015 · Cochrane Headline outcomes only
RR 2.53
11 studies · 1437 participants
Low

Non‐platinum therapies vs platinum combination

Grade 3 or higher hematological toxicity for platinum therapies ‐ thrombocytopenia · non‐small cell lung cancer in the elderly population

Non‐platinum therapies may leads to higher grade 3 or higher hematological toxicity for platinum therapies ‐… compared with platinum combination (low certainty).

1 finding from 1 review

Chemotherapy for advanced non‐small cell lung cancer in the elderly population 2015 · Cochrane Headline outcomes only
RR 3.59
9 studies · 1260 participants
Low

Non‐platinum therapies vs platinum combination

Grade 3 or higher Non‐Hematological Toxicity for Platinum‐based therapies ‐ Peripheral neuropathy · non‐small cell lung cancer in the elderly population

Non‐platinum therapies may leads to higher grade 3 or higher Non‐Hematological Toxicity for Platinum‐based… compared with platinum combination (low certainty).

1 finding from 1 review

Chemotherapy for advanced non‐small cell lung cancer in the elderly population 2015 · Cochrane Headline outcomes only
RR 7.02
5 studies · 776 participants
Low

Non‐platinum therapies vs platinum combination

1‐Year survival rate · non‐small cell lung cancer in the elderly population

Non‐platinum therapies probably leads to lower 1‐Year survival rate compared with platinum combination (moderate certainty).

1 finding from 1 review

Chemotherapy for advanced non‐small cell lung cancer in the elderly population 2015 · Cochrane Headline outcomes only
RR 0.89
13 studies · 813 participants
Moderate

Non‐platinum therapies vs platinum combination

Progression‐free survival · non‐small cell lung cancer in the elderly population

Non‐platinum therapies may leads to lower progression‐free survival compared with platinum combination (low certainty).

1 finding from 1 review

Chemotherapy for advanced non‐small cell lung cancer in the elderly population 2015 · Cochrane Headline outcomes only
HR 0.76
9 studies · 9 participants
Low

Non‐platinum therapies vs platinum combination

Objective response rate · non‐small cell lung cancer in the elderly population

Non‐platinum therapies probably leads to higher objective response rate (ORR) compared with platinum combination (moderate certainty).

1 finding from 1 review

Chemotherapy for advanced non‐small cell lung cancer in the elderly population 2015 · Cochrane Headline outcomes only
RR 1.57
11 studies · 1432 participants
Moderate

Non‐platinum therapies vs platinum combination

QoL · non‐small cell lung cancer in the elderly population

1 finding from 1 review

Chemotherapy for advanced non‐small cell lung cancer in the elderly population 2015 · Cochrane Headline outcomes only
no estimate extracted
5 studies · 5 participants
GRADE not reported

Non‐platinum therapies vs platinum combination

Overall survival · non‐small cell lung cancer in the elderly population

Non‐platinum therapies probably leads to lower overall survival compared with platinum combination (moderate certainty).

1 finding from 1 review

Chemotherapy for advanced non‐small cell lung cancer in the elderly population 2015 · Cochrane Headline outcomes only
HR 0.76
13 studies · 13 participants
Moderate